The bar chart illustrates the amount of money invested on research by Novas, Fleming, Biopharm, Avicenna and Pharm pharmaceutical companies in 2012, 2018 and predictions for 2022.
Overall, Novas consistently spent the most on research, with a significant increase over the years, while Pharm had the lowest investment. All companies showed an upward trend in research spending, but the growth rates varied.
According to the figures, Novas spent about $3 billion in 2012, which rose sharply to around $16 billion in 2018, and is expected to reach $57 billion in 2022. Fleming’s investment, the second highest, grew from $5 billion in 2012 to $15 billion in 2018, with a double increase to $30 billion expected in 2022.
Looking at the data more closely, Biopharm and Avicenna showed notable growth in their research budgets. Biopharm’s investment grew from $1 billion in 2012 to $6 billion in 2018, with a rise to $25 billion forecasted in 2022. Avicenna increased its investment from $3 billion in 2012 to $11 billion in 2018, and steady growth is expected moving forward in 2022. Pharm consistently had the lowest changes, rising gradually from about $9 billion in 2012 to just under $12 billion in 2018, although significant growth to $21 billion is forecasted in 2022.